SBI993 是 SBI-477 的类似物，可用作生物标志物来确认 MondoA 靶基因在体内表达的预期作用。 SBI993 降低肌肉 TAG 水平和肝脂肪变性。

SBI993 is an analog of SBI-477 and can be used as a biomarker to confirm the expected action of MondoA target gene expression in vivo. SBI993 reduces muscle TAG levels and hepatic steatosis.

SBI-993 reduces the expression of TXNIP and ARRDC4 in human myotubes[1].

SBI993 (50 mg/kg; s.c.) shows a reduction of the expression of TAG synthesis and lipogenic genes in both muscle and liver. SBI993 reduces Txnip and Arrdc4 expression especially robust in liver. Occupation of both ChREBP and MondoA on the Txnip and pyruvate kinase (Pklr) gene promoters was reduced in liver by SBI993[1].

2073059-56-8

C23H23N3O5S

453.51

SBI993

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years